All In Biotech

Drug Trial Radar · NCT06616974

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 191 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

191

Planned (sponsor's estimate)

Start

Sep 4, 2024

Primary completion

Nov 24, 2026

Study completion Jan 5, 2027

Sponsor

Lead sponsor
Tectonic TherapeuticIndustry
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 83 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).

Conditions

  • Pulmonary Hypertension
  • Heart Failure With Preserved Ejection Fraction

Interventions

  • TX000045- Dose ADrug

    The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.

  • TX000045- Dose BDrug

    The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.

  • PlaceboDrug

    The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH).Time frame: Baseline up to Week 24 post first dose
  2. Assess safety of TX000045 by the incidence of adverse events, adverse events of special interest and SAEs.Time frame: Baseline up to Week 30 post first dose
  3. Number of participants with abnormal laboratory values and/or adverse events that are related to treatment.Time frame: Baseline up to Week 30 post first dose
  4. Number of participants with treatment-related adverse events.Time frame: Baseline up to Week 30 post first dose
  5. Number of participants with changes in the physical examination findings.Time frame: Baseline to Week 30 post first dose

Locations

72 sites in 17 countries. Site status is shown where the registry gives one.

  • Phoenix

    Phoenix, Arizona

  • Scottsdale

    Scottsdale, Arizona

  • San Francisco

    San Francisco, California

  • Santa Rosa

    Santa Rosa, California

  • Aurora

    Aurora, Colorado

  • Jacksonville

    Jacksonville, Florida

  • Augusta

    Augusta, Georgia

  • McDonough

    McDonough, Georgia

  • Boise

    Boise, Idaho

  • USA

    Louisville, Kentucky

  • Baltimore

    Baltimore, Maryland

  • Boston

    Boston, Massachusetts

  • Minneapolis

    Minneapolis, Minnesota

  • St Louis

    St Louis, Missouri

  • Omaha

    Omaha, Nebraska

  • New York

    New York, New York

  • New York

    New York, New York

  • Durham

    Durham, North Carolina

  • Philadelphia

    Philadelphia, Pennsylvania

  • Pittsburgh

    Pittsburgh, Pennsylvania

  • York

    York, Pennsylvania

  • Port Arthur

    Port Arthur, Texas

  • Waco

    Waco, Texas

  • Salt Lake City

    Salt Lake City, Utah

  • United States

    Norfolk, Virginia

  • Yerevan

    Yerevan, Armenia

  • Yerevan

    Yerevan, Armenia

  • Yerevan

    Yerevan, Armenia

  • Camperdown

    Camperdown, Australia

  • New Lambton

    New Lambton, Australia

  • Camperdown

    Camperdown, New South Wales, Australia

  • Macquarie

    Macquarie, New South Wales, Australia

  • New Lambton

    New Lambton, New South Wales, Australia

  • Sydney

    Sydney, New South Wales, Australia

  • Wollongong

    Wollongong, New South Wales, Australia

  • Chermside

    Chermside, Queensland, Australia

  • Hobart

    Hobart, Tasmania, Australia

  • Malvern

    Malvern, Victoria, Australia

  • Austria

    Vienna, Austria

  • Brussel

    Brussels, Belgium

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.